ABSTRACT
With the advent of recombinant DNA technology, protein-based drugs have become continually and increasingly commonplace in the repertoire of medicines available to medical practitioners for the treatment of a wide range of diseases from cancer to rheumatoid arthritis. Along with the scientific and technical advances in the production of recombinant proteins, the principal reason for the success of protein drugs is their high specificity towards targets and superior safety profiles when compared to their small molecule counterparts.
